Paper Details

  1. Home
  2. Paper Details

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.

Author: BarbanojM, BerthierM L, Estévez-GonzálezA, García-SánchezC, GironellA, KulisevskyJ, Pascual-SedanoB

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Both levodopa and pergolide treatments were associated with a long-lasting improvement in motor scores and cognitive tasks. However, the improvement in cognitive tasks was not sustained at 24 months, suggesting that dopaminergic replacement is not enough to compensate for all cognitive deficits.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The cognitive effects of dopaminergic treatment in Parkinson's disease (PD) are still controversial. OBJECTIVE: To evaluate, in previously untreated patients with PD, whether chronic dopaminergic stimulation produces significant cognitive changes; whether they are sustained beyond the p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/1531-8257(200007)15:4<613::aid-mds1005>3.0.co;2-f

データ提供：米国国立医学図書館（NLM）

The Cognitive Landscape of Dopaminergic Replacement in Parkinson's Disease

The quest to understand and treat Parkinson's disease (PD) is a complex and fascinating journey. This study delves into the cognitive effects of dopaminergic replacement therapy, exploring whether chronic stimulation with levodopa or pergolide has a lasting impact on cognitive function in patients with PD. The authors followed previously untreated PD patients for two years, assessing their cognitive performance over time.

Dopaminergic Replacement Offers Temporary Cognitive Benefits

The study revealed that both levodopa and pergolide led to improvements in motor function and certain cognitive domains, including learning and long-term memory. However, these cognitive benefits were not sustained over the two-year period. While motor improvements persisted, cognitive function seemed to regress over time. This suggests that while dopaminergic replacement can provide some temporary cognitive benefits, it may not fully address the cognitive deficits associated with PD.

Navigating the Cognitive Challenges of PD

This research sheds light on the complex interplay between dopaminergic replacement and cognitive function in PD. The findings suggest that while dopaminergic therapy can offer temporary cognitive benefits, it may not be a long-term solution for cognitive decline. It's important for patients with PD to discuss these potential effects with their healthcare providers and explore other strategies for managing cognitive challenges.

Dr. Camel's Conclusion

This research reminds us that the journey with PD can be like a desert trek: there may be periods of respite and improvement, but challenges can arise. Dopaminergic therapy can provide a temporary oasis, but continuous exploration of strategies to address cognitive decline is crucial for navigating the landscape of this complex condition.

Date :
  1. Date Completed 2001-01-11
  2. Date Revised 2019-10-25
Further Info :

Pubmed ID

10928571

DOI: Digital Object Identifier

10.1002/1531-8257(200007)15:4<613::aid-mds1005>3.0.co;2-f

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.